These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 38561109)

  • 1. Fixed-dose combination therapy in pulmonary arterial hypertension: Pros & cons.
    Manzi G; Recchioni T; Badagliacca R; Papa S; Vizza CD
    Int J Cardiol; 2024 Jul; 406():132003. PubMed ID: 38561109
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of rapid sequential combination therapy on distinct haemodynamic measures in newly diagnosed pulmonary arterial hypertension.
    Kramer T; Nattmann P; Gerhardt F; Stafiej P; Dumitrescu D; Ten Freyhaus H; Wißmüller M; Hohmann C; Baldus S; Rosenkranz S
    ESC Heart Fail; 2024 Jun; 11(3):1540-1552. PubMed ID: 38224960
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of Combination Therapy of Endothelin Receptor Antagonist and Phosphodiesterase-5 Inhibitor on Clinical Outcome and Pulmonary Haemodynamics in Patients with Pulmonary Arterial Hypertension: A Meta-Analysis.
    Kirtania L; Maiti R; Srinivasan A; Mishra A
    Clin Drug Investig; 2019 Nov; 39(11):1031-1044. PubMed ID: 31420854
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Bayesian Network Meta-analysis of Add-on Drug Therapies Specific for Pulmonary Arterial Hypertension.
    Petrovič M; Locatelli I
    Ann Pharmacother; 2020 May; 54(5):423-433. PubMed ID: 31735058
    [No Abstract]   [Full Text] [Related]  

  • 5. Risk Reduction and Hemodynamics with Initial Combination Therapy in Pulmonary Arterial Hypertension.
    Badagliacca R; D'Alto M; Ghio S; Argiento P; Bellomo V; Brunetti ND; Casu G; Confalonieri M; Corda M; Correale M; D'Agostino C; De Michele L; Galgano G; Greco A; Lombardi C; Manzi G; Mercurio V; Mulè M; Paciocco G; Papa S; Romeo E; Scelsi L; Stolfo D; Vitulo P; Naeije R; Vizza CD
    Am J Respir Crit Care Med; 2021 Feb; 203(4):484-492. PubMed ID: 32857597
    [No Abstract]   [Full Text] [Related]  

  • 6. Effectiveness and safety of endothelin receptor antagonists, alone and in combination therapy, in the pulmonary arterial hypertension-connective tissue disease subtype: A systematic review and meta-analysis.
    Shivakumar S; Thynne TR; Mohammadi L; Burdeniuk C; Mangoni AA
    Int J Rheum Dis; 2020 Oct; 23(10):1276-1287. PubMed ID: 32691518
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association Between Initial Oral Therapy and Outcomes in Systemic Sclerosis-Related Pulmonary Arterial Hypertension.
    Lammi MR; Mathai SC; Saketkoo LA; Domsic RT; Bojanowski C; Furst DE; Steen VD;
    Arthritis Rheumatol; 2016 Mar; 68(3):740-8. PubMed ID: 26479414
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-Life Experience with Selexipag as an Add-On Therapy to Oral Combination Therapy in Patients with Pulmonary Arterial or Distal Chronic Thromboembolic Pulmonary Hypertension: A Retrospective Analysis.
    Berlier C; Schwarz EI; Saxer S; Lichtblau M; Ulrich S
    Lung; 2019 Jun; 197(3):353-360. PubMed ID: 30963265
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized Trial of Macitentan/Tadalafil Single-Tablet Combination Therapy for Pulmonary Arterial Hypertension.
    Grünig E; Jansa P; Fan F; Hauser JA; Pannaux M; Morganti A; Rofael H; Chin KM
    J Am Coll Cardiol; 2024 Jan; 83(4):473-484. PubMed ID: 38267108
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phosphodiesterase 5 inhibitors for pulmonary hypertension.
    Barnes H; Brown Z; Burns A; Williams T
    Cochrane Database Syst Rev; 2019 Jan; 1(1):CD012621. PubMed ID: 30701543
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advances in targeted therapy for pulmonary arterial hypertension in children.
    Li L; Zhu X; Chen X; Gao J; Ding C; Zhang M; Ma S
    Eur J Pediatr; 2023 May; 182(5):2067-2076. PubMed ID: 36527480
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gender-related differences in pulmonary arterial hypertension targeted drugs administration.
    Marra AM; Benjamin N; Eichstaedt C; Salzano A; Arcopinto M; Gargani L; D Alto M; Argiento P; Falsetti L; Di Giosia P; Isidori AM; Ferrara F; Bossone E; Cittadini A; Grünig E
    Pharmacol Res; 2016 Dec; 114():103-109. PubMed ID: 27771466
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients receiving background endothelin receptor antagonist and phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C2 study): a randomized controlled trial.
    Tapson VF; Jing ZC; Xu KF; Pan L; Feldman J; Kiely DG; Kotlyar E; McSwain CS; Laliberte K; Arneson C; Rubin LJ;
    Chest; 2013 Sep; 144(3):952-958. PubMed ID: 23669822
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early Addition of Selexipag to Double Therapy for Pulmonary Arterial Hypertension.
    Burger CD; Tang W; Tsang Y; Panjabi S
    JAMA Netw Open; 2024 Sep; 7(9):e2434691. PubMed ID: 39312239
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Medical treatment of pulmonary hypertension: what's new?].
    Richter MJ; Gall H; Tello K; Sommer N; Seeger W; Grimminger F; Ghofrani HA
    Internist (Berl); 2015 May; 56(5):573-82. PubMed ID: 25924799
    [TBL] [Abstract][Full Text] [Related]  

  • 16. What is the position of pulmonary arterial hypertension-specific drug therapy in patients with Eisenmenger syndrome: A systematic review and meta-analysis.
    Li Q; Kuang HY; Wu YH; Lu TW; Yi QJ
    Medicine (Baltimore); 2019 May; 98(20):e15632. PubMed ID: 31096477
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and/or phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C study): a randomized controlled trial.
    Tapson VF; Torres F; Kermeen F; Keogh AM; Allen RP; Frantz RP; Badesch DB; Frost AE; Shapiro SM; Laliberte K; Sigman J; Arneson C; Galiè N
    Chest; 2012 Dec; 142(6):1383-1390. PubMed ID: 22628490
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the combination of endothelin receptor antagonists (ERA) and phosphodiesterase-5 inhibitors for the treatment of pulmonary arterial hypertension (PAH) in pathologic human pulmonary arteries in an ex-vivo organ bath model.
    Englert L; Stadlbauer C; Spaeth M; Hofmann HS; Schneider C; Hatz RA; Preissler G; Michel S; Golovchenko S; Ried M; Hoenicka M
    Pulm Pharmacol Ther; 2021 Feb; 66():101985. PubMed ID: 33359621
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral targeted therapies in the treatment of pulmonary arterial hypertension: a meta-analysis of clinical trials.
    Zheng YG; Ma H; Hu EC; Liu G; Chen G; Xiong CM
    Pulm Pharmacol Ther; 2014 Dec; 29(2):241-9. PubMed ID: 25173912
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination therapy versus monotherapy for pulmonary arterial hypertension: a meta-analysis.
    Lajoie AC; Lauzière G; Lega JC; Lacasse Y; Martin S; Simard S; Bonnet S; Provencher S
    Lancet Respir Med; 2016 Apr; 4(4):291-305. PubMed ID: 26935844
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.